The FDA has approved a change to the labeling for a Pfizer birth control shot that warns patients of the risk of meningioma, ...
Pfizer faces a lawsuit in which women allege the drugmaker failed to warn them about the risks of meningioma associated with ...
The FDA contacted J&J right after ASH to discuss using a special fast pass on a multiple myeloma regimen. Elsewhere, a new ...
Pfizer, which makes the shot, is fighting a lawsuit from more than 1,000 women who claim the company knew about the risk of meningiomas but failed to warn patients. Meanwhile, former Vice President ...
Pfizer's coronavirus vaccine could face some headwinds in the near future. The company will enter a period of patent cliffs ...
Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click ...
Pfizer Inc. is rated a Hold due to structural challenges despite recent 12% total return and compelling 6.7% dividend yield.
Pfizer Is Still Struggling to Replace Its COVID Revenue. Here's What We Could See From the Pharmaceutical Giant in 2026. Keep ...
Pfizer bets on YaoPharma’s oral GLP-1 pill YP05002 after past failures, aiming to rejoin the booming $150B obesity-drug market.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback